Protillion Biosciences

Executive Summary

Protillion Biosciences is a private, early-stage biotechnology company headquartered in San Diego, California, focused on transforming therapeutic antibody discovery and optimization through high-throughput quantitative protein data. Founded in 2018, the company leverages proprietary technology to measure protein interactions at unprecedented scale and speed, aiming to replace traditional trial-and-error methods with data-driven insights. By generating deep quantitative datasets, Protillion enables the identification of superior antibody candidates with improved affinity, specificity, and developability, potentially accelerating the path from target to clinic. The company's platform addresses a critical bottleneck in biologics R&D, where conventional screening often fails to capture the full complexity of protein interactions. While Protillion has not disclosed specific funding rounds or valuation, its positioning within the competitive antibody discovery space suggests ongoing efforts to secure partnerships or financing to advance its technology. The company's approach aligns with industry trends toward machine learning and high-content screening, positioning it as a potential enabler for large biopharma seeking to enhance their therapeutic pipelines.

Upcoming Catalysts (preview)

• Q4 2026Series A Financing60% success
• H1 2027Pharmaceutical Partnership for Antibody Discovery40% success
• Q3 2026Publication of Platform Benchmarking Data70% success